ANCN vs. WHWK, SPRB, LITS, ELYM, AADI, ATNM, NBRV, PYRGF, TAOX, and LNAI
Should you be buying Anchiano Therapeutics stock or one of its competitors? The main competitors of Anchiano Therapeutics include Whitehawk Therapeutics (WHWK), Spruce Biosciences (SPRB), Lite Strategy (LITS), Eliem Therapeutics (ELYM), Aadi Bioscience (AADI), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), PyroGenesis Canada (PYRGF), Synaptogenix (TAOX), and Lunai Bioworks (LNAI).
Anchiano Therapeutics vs. Its Competitors
Whitehawk Therapeutics (NASDAQ:WHWK) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.
Anchiano Therapeutics has lower revenue, but higher earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Whitehawk Therapeutics had 5 more articles in the media than Anchiano Therapeutics. MarketBeat recorded 5 mentions for Whitehawk Therapeutics and 0 mentions for Anchiano Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.18 beat Anchiano Therapeutics' score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.
Whitehawk Therapeutics has a net margin of 99.42% compared to Anchiano Therapeutics' net margin of 0.00%. Anchiano Therapeutics' return on equity of 36.08% beat Whitehawk Therapeutics' return on equity.
52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Whitehawk Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.
Summary
Whitehawk Therapeutics beats Anchiano Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Anchiano Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ANCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anchiano Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ANCN) was last updated on 10/23/2025 by MarketBeat.com Staff
Free ANCN Stock Alerts